New drug KINE-101 tested in humans for first time
NCT ID NCT07343323
First seen Jan 15, 2026 · Last updated Jun 20, 2026 · Updated 21 times
Summary
This early-stage trial tested the safety of a new drug called KINE-101 in 40 healthy volunteers. Participants received a single dose either through a vein or under the skin. The main goal was to check for side effects and how the drug moves through the body. No treatment benefit was expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Parexel International
Baltimore, Maryland, 21225, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KINE-101
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.